Here are the New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
New evidence, new evidence act, new information on metformin, metformin in the news, breaking news about metformin, the truth about metformin, shroud of turin new evidence 2024, latest info on metformin, new evidence in jonbenet case.
New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis
Purpose: The potential efficacy of metformin in breast cancer (BC) has been hotly discussed but never conclusive. This genetics-based study aimed to evaluate the relationships between metformin targets and BC risk.
Methods: Metformin targets from DrugBank and genome-wide association study (GWAS) data from IEU OpenGWAS and FinnGen were used to investigate the breast cancer (BC)-metformin causal link with various Mendelian Randomization (MR) methods (e.g., inverse-variance-weighting). The genetic association between type 2 diabetes (T2D) and the drug target of metformin was also analyzed as a positive control. Sensitivity and pleiotropic tests ensured reliability.
Results: The primary targets of metformin are PRKAB1, ETFDH and GPD1L. We found a causal association between PRKAB1 and T2D (odds ratio [OR] 0.959, P = 0.002), but no causal relationship was observed between metformin targets and overall BC risk (PRKAB1: OR 0.990, P = 0. 530; ETFDH: OR 0.986, P = 0.592; GPD1L: OR 1.002, P = 0.806). A noteworthy causal relationship was observed between ETFDH and estrogen receptor (ER)-positive BC (OR 0.867, P = 0.018), and between GPD1L and human epidermal growth factor receptor 2 (HER2)-negative BC (OR 0.966, P = 0.040). Other group analyses did not yield positive results.
Conclusion: The star target of metformin, PRKAB1, does not exhibit a substantial causal association with the risk of BC. Conversely, metformin, acting as an inhibitor of ETFDH and GPD1L, may potentially elevate the likelihood of developing ER-positive BC and HER2-negative BC. Consequently, it is not advisable to employ metformin as a standard supplementary therapy for BC patients without T2D. © The Author(s) 2024.
Authors : Xu J.-X.; Zhu Q.-L.; Bi Y.-M.; Peng Y.-C.
Source : BioMed Central Ltd
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1186/s12885-024-12453-w |
| ISSN | 14712407 |
| Volume | 24 |
You can download the article here
If You have any problem, contact us here